Is Bionano Genomics going out of business?

Bionano Genomics, Inc. (BNGO) Fundamentals

A quick summary of the latest filed figures while the full analysis loads.

Bionano Genomics, Inc. (BNGO) scores 22 out of 100 on fundamentals, Distressed / Caution, based on SEC filing data.

Leading signal: Shares dilution YoY: 266.91% (YoY) - Heavy dilution suggests continuous equity raises; survival depends on external capital.

Five questions, kept separate

Survival - Critical

1-2 mo of estimated runway from 2026-06-30, based on $3.7M of cash and short-term investments against $32.4M of annual burn. Adjusted shares outstanding increased 266.9% over the comparison year.

Business quality - Poor

-116.9% operating margin and -113.8% FCF margin produce a poor Business Quality assessment.

Trajectory - Accelerating

Revenue, operating margin and cash margin improved together. Revenue improved 10.0%; operating margin improved 156.2pp; FCF margin improved 176.6pp. The TTM window includes a mixed-basis Q4 estimate.

Valuation - Extreme expectations

-862.3% normalized FCF yield supports an extreme expectations Valuation assessment on the annual basis.

Event risk - Critical event risk

Going-Concern Warning is the decisive filing event; one adverse event family is active. It appears across 2 scanned filings. Favorable events are shown separately and do not offset adverse risk.

What the rules read

• Shares dilution YoY: 266.91% (YoY) - Heavy dilution suggests continuous equity raises; survival depends on external capital.
• Debt / Equity: 0.21x
• ROE quality: -83.51%
• ROIC: -88.34%
• Filing event risk: Going-Concern Warning (-8 pts)
• Gross margin (industrial): 46.25%
• R&D intensity: 31.47%
• Revenue growth YoY: 21.36% (Industrial YoY) - Growth from a low base; sustainability uncertain.
• Return on Assets: -55.46%
• Asset Efficiency: 0.60x
• Revenue per Asset Efficiency: 66.39% QoQ (Strong monetization)
• Net income trend: -8.25%

Read from filings through 2026-08-10.

Price as of 2026-09-11.